Gastroesophageal Reflux Clinical Trial
Official title:
The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux
This is a continuation of a study that has already been completed in the division of gastroenterology (GI) looking at the effects of sleep medication zolpidem (Ambien) on subjects with Gastroesophageal reflux disease (GERD). That study looked at 16 subjects, 8 who had been diagnosed with GERD and 8 who did not have GERD (IRB Control #04S.41). All subjects previously had a PH probe completed in the division of GI at Thomas Jefferson University. An additional 8 subjects with GERD will be recruited to obtain more data to add to the previous study results. These subjects will undergo 2 sleep studies, one in which they will be given Ambien and one in which they will not.
The use of hypnotic medications for the treatment of insomnia has increased as has the
incidence of gastroesophageal reflux disease (GERD) and its complications. Nocturnal acid
reflux is associated with severe injuries such as narrowing of the esophagus, inflammation
and cancer of the esophagus.
A Gallup survey conducted in 2000, on behalf of the American Gastroenterological Association,
found that 79% of respondents reported heartburn at night and 75% reported that symptoms
affected their sleep. The impact that hypnotic medications (sleep medications) have on
nocturnal reflux has not been well established. Orr et al. demonstrated that sleep arousal is
critical in clearing acid from the esophagus and that decreased wakefulness results in
prolonged esophageal acid exposure. Singh et al. showed that use of the hypnotic alprazolam,
increases esophageal acid exposure time, possibly by blunting arousal and thereby interfering
with acid clearance mechanisms. No study has examined sleep architecture and pattern (i.e.
polysomnography) with and without hypnotic medication use and correlated this with how long
the esophagus is exposed to acid.
Esophageal motility, gravity and salivation are three primary mechanisms by which acid is
removed from the esophagus. Blunting nocturnal arousal with hypnotic medications may
exacerbate gastroesophageal reflux or trigger it in otherwise healthy subjects, independent
of any effects the medication may have on lower esophageal sphincter pressure. By depressing
consciousness with pharmacologic agents (i.e. hypnotics, anxiolytics, antipsychotics) the
body's defense against esophageal acid clearance may be impaired. Primary peristalsis,
salivation and the warning symptoms of GERD are lost, thereby exposing the esophagus to a
greater number and duration of GERD events.
The potential deleterious effects that hypnotic medications may have on nocturnal GERD has
important implications on understanding the impact that hypnotic medications have on GERD.
The aim of this pilot study is to evaluate the effect that zolpidem (Ambien) has on sleep
pattern, nocturnal GERD and symptoms.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |